Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359

Benzinga Newsdesk www.benzinga.com Negative 59.5%

Neg 59.5% Neu 0% Pos 0%

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.